SNGX (soligenix.com) Net earnings per share (EPS TTM)

soligenix.com (SNGX) - corporate logo

Soligenix, Inc. (SNGX) relies on exclusive government orders for RiVax, creating an unrivaled sales channel. In the short term, pricing power is driven by the unique thermostabilization of its drugs, while the long-term business is based on a protected ecosystem. The 12-month EPS trend captures this balance, where the current parameter equals -0.75. Stability is further confirmed by FDA orphan drug designations and a 100% patient retention rate in clinical trials.

SNGX (BioPharma Bio) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/13/2026

Soligenix Inc (SNGX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart BioPharma Bio|SNGX - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Soligenix, Inc.|SNGX - Full Business Value
- business book valuation details:
Book Value per Share Soligenix|SNGX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio soligenix.com|SNGX - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Soligenix, Inc.|SNGX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital BioPharma Bio|SNGX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Soligenix, Inc.|SNGX - Long-Term Debt|Company Short-Term Debt Soligenix|Quick Liquidity soligenix.com
- net income and valuation multiples indicators:
SNGX - Net Financial Result|Expected Profit Soligenix, Inc.|SNGX - Business Payback Period|Future Price to Earnings BioPharma Bio|SNGX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Soligenix, Inc.|SNGX - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Soligenix|SNGX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth soligenix.com|SNGX - Net earnings per share change in current year|Earnings growth forecast for next year Soligenix, Inc.
- revenue and sales proceeds data:
SNGX - Company Total Revenue|Company Projected Revenue BioPharma Bio|SNGX - Market Cap to Revenue Ratio|Forward P/S Multiple Soligenix, Inc.
Fundamental company analysis:SNGX - soligenix.com
Flagship merchandise of Soligenix Inc

Professional asset selection begins with an analysis of the real yield of each security. This metric calculates annual net profit divided by the total number of shares, accounting for share buybacks. By analyzing the 12-month trend of net income per share, an investor can see the company's actual equity earnings. For Soligenix, Inc. (SNGX), the stability of this metric is supported by long-term US government contracts in the field of biosecurity. The upward trend confirms the effectiveness of the commercialization of radiation countermeasures.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (modernatx.com) - Earnings per share for the last 12 months|PCVX: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months TARS (Tarsus Pharmaceuticals Inc)|CRMD (CorMedix Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Seres Therapeutics, Inc MCRB|Net earnings per share (EPS TTM) SPRO|Net earnings per share for the last 12 months scynexis.com SCYX|AN2 Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters PYPD (PolyPid Ltd)|YS Biopharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Iterum Therapeutics plc ITRM|biomx.com (PHGE) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharmaceuticals, Inc. (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Inc)